Pharma Exclusives Pressreleases
Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition
Wednesday, July 16, 2025Aptar Pharma a global leader in drug delivery and active material science solutions and services today announces its acquisition of the clinical trial materials manufacturing capabilities of Mod Pharma
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
Tuesday, July 15, 2025Merck known as MSD outside of the United States and Canada today announced the initiation of the EXPrESSIVE Phase clinical trials evaluating the safety and efficacy of MK an investigational oncemonthly
Thermo Fisher Scientific Introduces the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to Help Advance the Future of Precision Medicine
Tuesday, July 15, 2025Thermo Fisher Scientific announced that the Oncomine Comprehensive Assay Plus is now available on the Ion Torrent Genexus System helping accelerate precision oncology research
Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
Monday, July 14, 2025Positive highlevel results from the BaxHTN Phase III trial showed baxdrostat at two doses mg and mg demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure SBP
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Monday, July 14, 2025Takeda today announced that all primary and secondary endpoints were met in two Phase randomized doubleblind placebocontrolled studies of oveporexton TAK a potential firstinclass investigational oral orexin receptor
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
Monday, July 14, 2025BioTechne Corporation today announced that its Simple Western Technology played a key role in supporting the FDA approval of ZEVASKYN prademagene zamikeracel the first autologous cellbased gene therapy for patients
Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025
Thursday, July 10, 2025Tonix Pharmaceuticals Holding Corp a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates today announced the presentation of new findings on TNX
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome
Thursday, July 10, 2025Biogen Inc and Stoke Therapeutics Inc Nasdaq STOK a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine today announced the presentation of data from an analysis that informed the design
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Wednesday, July 09, 2025Longeveron Inc a clinical stage regenerative medicine biotechnology company developing cellular therapies for lifethreatening and chronic agingrelated conditions today announced that the US Food and Drug Administration
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth
Wednesday, July 09, 2025Merck known as MSD outside of the United States and Canada and Verona Pharma plc Nasdaq VRNA Verona Pharma a biopharmaceutical company focused on respiratory diseases today announced that the companies
